Cellectar Biosciences Inc (CLRB)

[Crusader]

Nullification of a post as to form does not

Nullify its content:

The Globe Newswire PR from today states this:

“...Last month, Cellectar announced that the FDA also granted RPDD for CLR 131 for the treatment of neuroblastoma. If CLR 131 is approved by the FDA for either neuroblastoma or rhabdomyosarcoma, the rare pediatric disease designation may enable Cellectar to receive a priority review voucher. Priority review vouchers can be used by the sponsor to receive priority review for a future NDA or BLA submission, which would reduce the FDA review time from 12 months to six months. Currently, these vouchers can also be transferred or sold to another entity. Over the last 16 months, five priority review vouchers were sold for between $110 million to $150 million each.”...

What’s not to like about this development as a long CLRB stock holder?

Don’t believe everything one reads on the Internet is a good rule of thumb, however.